Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.74 |
| ▸ | CD44 | P16070 | 2/20 | 0.74 |
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2876610 | 0.98 | PNMT (0.71) | PNMTCD44MAOBTSHRHTR2C | |
| Ammonia Solution, Strong SCHEMBL20359732 | 0.98 | PNMT (0.71) | PNMTCD44MAOBTSHRHTR2C | |
| SCHEMBL4503618 | 0.93 | CD44 (0.71) | PNMTCD44MAOBTSHRHTR2C | |
| SCHEMBL4502101 | 0.91 | CD44 (0.68) | PNMTCD44MAOBTSHRHTR2C | |
| SCHEMBL4505345 | 0.87 | HTR2C (0.70) | PNMTCD44MAOBTSHRHTR2C | |
| SCHEMBL23555060 | 0.86 | PNMT (0.83) | PNMTCD44MAOBHTR2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL18419929 | 0.86 | PNMT (0.83) | PNMTCD44MAOBHTR2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.85 | PNMT (1.00) | PNMTCD44MAOBHTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | claimed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | claimed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | claimed |
| JP-4778420-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | claimed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | claimed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| EP-1615633-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-07-09 | — | — | EP | claimed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | claimed |
| EP-1615633-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-01-18 | — | — | EP | claimed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | claimed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | claimed |
| WO-2004093817-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-11-04 | — | — | WO | claimed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | claimed |
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | claimed |
| WO-1992019572-A2 | I-AZA-2-PHENYLHYDRORAZINO-HETEROCYCLES, PROCESS FOR PRODUCING THEM AND PHARMACEUTICALS CONTAINING THEM | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1992-11-12 | — | — | WO | claimed |
| US-5084453-A | Antibiotics, bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | PNMT 4578/4885CD44 4296/4885MAOB 4018/4885 |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | PNMT 2231/4885CD44 4688/4885MAOB 1021/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | PNMT 3898/4885CD44 4194/4885MAOB 1496/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | PNMT 3383/4885CD44 4196/4885MAOB 2901/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | PNMT 4404/4885CD44 4687/4885MAOB 269/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | PNMT 3616/4885CD44 4859/4885MAOB 932/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | PNMT 2231/4885CD44 4688/4885MAOB 1021/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | PNMT 3424/4885CD44 137/4885MAOB 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.